Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $21.9 million.

  • Fennec Pharmaceuticals' Cash & Equivalents fell 4556.8% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 4556.8%. This contributed to the annual value of $26.6 million for FY2024, which is 10072.35% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Cash & Equivalents stood at $21.9 million for Q3 2025, which was down 4556.8% from $18.7 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Cash & Equivalents high stood at $51.2 million for Q1 2024, and its period low was $12.4 million during Q3 2023.
  • Over the past 5 years, Fennec Pharmaceuticals' median Cash & Equivalents value was $23.2 million (recorded in 2022), while the average stood at $24.6 million.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Cash & Equivalents crashed by 5832.55% in 2023, and later surged by 28574.12% in 2024.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Cash & Equivalents stood at $24.3 million in 2021, then fell by 2.31% to $23.8 million in 2022, then plummeted by 44.19% to $13.3 million in 2023, then surged by 100.72% to $26.6 million in 2024, then fell by 17.6% to $21.9 million in 2025.
  • Its Cash & Equivalents was $21.9 million in Q3 2025, compared to $18.7 million in Q2 2025 and $22.7 million in Q1 2025.